论文部分内容阅读
目的:探讨促红细胞生成素辅助治疗尿毒症血透患者临床分析。方法:选取近2年于我院进行血液透析的32例尿毒症患者为研究对象,将其随机分为观察组和对照组各16例,对照组给予血液透析治疗及一般常规治疗,观察组治疗在对照组治疗基础上加用促红细胞生成素治疗。2组均于治疗4个月后观察血红蛋白、红细胞数、红细胞压积、血清铁蛋白及转铁蛋白饱和度变化。结果:观察组血红蛋白、红细胞数、红细胞压积、血清铁蛋白及转铁蛋白饱和度升高均较对照组明显(P<0.05),具有明显差异性。结论:促红细胞生成素的使用有助于改善血液透析患者临床疗效,临床上可广泛应用。
Objective: To investigate the clinical analysis of erythropoietin adjuvant treatment of uremic hemodialysis patients. Methods: Twenty-two cases of uremia patients who underwent hemodialysis in our hospital for nearly 2 years were selected as study subjects. They were randomly divided into observation group and control group, with 16 cases in each group. The control group was given hemodialysis and conventional treatment, In the control group based on the plus use of erythropoietin therapy. Two groups were observed after 4 months of hemoglobin, red blood cell count, hematocrit, serum ferritin and transferrin saturation changes. Results: The hemoglobin, erythrocyte number, hematocrit, serum ferritin and transferrin saturation in the observation group were significantly higher than those in the control group (P <0.05), with significant differences. Conclusion: The use of erythropoietin can help to improve the clinical efficacy of hemodialysis patients, which can be widely used clinically.